Sort   by:  
 Page size 
TranscriptomicsGenome-wide DNA methylation in MDS/secondary AML and de novo AML
An increasing body of work reveals aberrant hypermethylation of genes occurring in and potentially contributing to the pathogenesis of myeloid malignancies. Several of these diseases, such as myelodysplastic syndromes (MDS), are responsive to DNA methyltransferase inhibitors. In order to determine ...
ORGANISM(S): Homo sapiens 
2010-05-15 | E-GEOD-17328 | biostudies-arrayexpress
TranscriptomicsMultilineage dysplasia and AML with mutated nucleophosmin
Multilineage dysplasia (MLD) has no impact on biological, clinico-pathological and prognostic features of AML with mutated nucleophosmin (NPM1) NPM1-mutated AML is a provisional entity in the WHO-2008 classification of myeloid neoplasms. The significance of concomitant multilineage dysplasia (MLD) i...
ORGANISM(S): Homo sapiens 
2010-07-30 | E-GEOD-18018 | biostudies-arrayexpress
TranscriptomicsAML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping features
AML with mutated NPM1 usually carries normal karyotype (NK) but it may harbor chromosomal aberrations whose significance remains unclear. We addressed this question in 631 AML patients with mutated/cytoplasmic NPM1. An abnormal karyotype (AK) was present in 93/631 cases (14.7%), the most frequent ab...
ORGANISM(S): Homo sapiens 
2009-06-01 | E-GEOD-16015 | biostudies-arrayexpress
TranscriptomicsGene expression profiling of CEBPA double-, single-mutant and CEBPA wild type AML
A previously predictive CEBPA double mutant (CEBPAdm) signature was hampered by the recently reported CEBPA silenced AML cases that carry a similar gene expression profile (GEP). Two independent AML cohorts were used to train and evaluate the predictive value of the CEBPAdm signature in terms of sen...
ORGANISM(S): Homo sapiens 
2011-08-03 | E-GEOD-22845 | biostudies-arrayexpress
TranscriptomicsGenotyping analysis of AML samples at diagnosis and relapse after Hematopoietic Stem Cell Transplantation (HSCT)
Genotype profiling of Acute Myeloid Leukemia samples. This dataset includes patients with diagnosis of de novo or secondary AML who experienced non-HLA loss disease relapse after allo-HCT, and for whom paired pre- and post-transplant viable leukemic samples were available.
ORGANISM(S): Homo sapiens 
2019-01-30 | E-MTAB-7631 | biostudies-arrayexpress
GenomicsIntegrative epigenomic analysis in MLL-AF9 acute myeloid leukemia (AML) and B-acute lymphoblastic leukemia (B-ALL)
Next generation DNA sequencing of acute myeloid leukemia (AML) patient samples has revealed novel recurrent mutations while at the same time highlighting the genetic heterogeneity of the disease. These observations suggest that an extraordinarily large number of combinations of mutations can contrib...
ORGANISM(S): Homo sapiens 
2017-05-02 | E-GEOD-70755 | biostudies-arrayexpress
TranscriptomicsTranscriptome analysis of AML samples at diagnosis and relapse after Hematopoietic Stem Cell Transplantation (HSCT)
Transcriptome profiling of Acute Myeloid Leukemia samples. This dataset includes patients with diagnosis of de novo or secondary AML who experienced non-HLA loss disease relapse after allo-HCT, and for whom paired pre- and post-transplant viable leukemic samples were available.
ORGANISM(S): Homo sapiens 
2019-01-29 | E-MTAB-7456 | biostudies-arrayexpress
TranscriptomicsTranscriptome analysis of AML samples at diagnosis and relapse after Hematopoietic Stem Cell Transplantation (HSCT)
Transcriptome profiling of Acute Myeloid Leukemia samples. This dataset includes patients with diagnosis of de novo or secondary AML who experienced non-HLA loss disease relapse after allo-HCT, and for whom paired pre- and post-transplant viable leukemic samples were available.
ORGANISM(S): Homo sapiens 
2019-01-31 | E-MTAB-7628 | biostudies-arrayexpress
TranscriptomicsTranscriptome analysis of AML samples at diagnosis and relapse after Hematopoietic Stem Cell Transplantation (HSCT)
Transcriptome profiling of Acute Myeloid Leukemia samples. This dataset includes patients with diagnosis of de novo or secondary AML who experienced non-HLA loss disease relapse after allo-HCT, and for whom paired pre- and post-transplant viable leukemic samples were available.
ORGANISM(S): Homo sapiens 
2019-01-31 | E-MTAB-7630 | biostudies-arrayexpress
ProteomicsAllogeneic antibodies specifically target AML antigen NuSAP1 after bone marrow transplantation
Identifying the targets of immune response after allogeneic hematopoietic cell transplantation (HCT) promises to provide relevant immune therapy candidate proteins. We used protein microarrays to serologically identify Nucleolar and Spindle Associated Protein 1 (NuSAP1) and Chromatin Assembly Factor...
ORGANISM(S): Homo sapiens 
2010-06-21 | E-GEOD-15255 | biostudies-arrayexpress
Sort   by:  
 Page size